We Think That There Are More Issues For Guangdong Biolight Meditech (SZSE:300246) Than Just Sluggish Earnings
Guangdong Biolight Meditech Co., Ltd.'s (SZSE:300246) stock rose after its recent weak earnings report. While shareholders may be willing to overlook soft profit numbers, we believe that they should
Medical Devices Maker Biolight Raises $83 Million From Share Placement
09:24 PM EST, 02/16/2022 (MT Newswires) -- Guangdong Biolight Meditech (SHE:300246) has raised 528 million yuan ($83.4 million) in net proceeds from the sale of shares in a private placement, accordi
The latest announcement of Paulette: net profit in 2021 is expected to decline by 77% and 83% compared with the same period last year.
Paulette announced that it is expected to make a profit of 60 million yuan to 78 million yuan in 2021, down 77.47% to 82.67% from the same period last year. Due to the impact of the epidemic, the company's revenue from health monitoring products in 2021 was significantly lower than that in 2020, and the sharp rise in the purchase price of chips in raw materials in 2021 led to a sharp increase in product costs. The chairman of the company is Yan Jinyuan. Mr. Yan Jinyuan: born in 1963, Chinese nationality, no permanent residence abroad, master's degree, senior engineer, associate professor, the products he presided over and designed have won the third prize of national invention of the State Science and Technology Commission and the second prize of scientific and technological progress of the State Education Commission.
Paulette's latest announcement: plans to set up an Innovation Research Institute
Paulette announced that the company intends to set up a wholly-owned subsidiary Guangdong Baolite High-end Medical device Innovation Research Institute Co., Ltd. (tentative name, company name subject to industrial and commercial registration, "Innovation Research Institute"). The registered capital of Innovation Research Institute is proposed to be 30 million yuan. After the completion of this investment, the company holds 100% equity interest in Innovation Research Institute. The company's main income was 783 million yuan, down 28.88% from the same period last year, the net profit from its mother was 69.3957 million yuan, down 77.96% from the same period last year, and the non-net profit was 66.8004 million yuan, down 78.17% from the same period last year, according to the company's 2021 quarterly report.
300246.SZ: awarding 280000 restricted shares to 21 motivators
300246.SZ announced on November 22nd that the conditions for granting restricted stock reserves stipulated in the company's 2021 restricted Stock incentive Plan (draft) have been fulfilled. According to the authorization of the first interim general meeting of shareholders in 2021, the 20th meeting of the Seventh Board of Directors of the company on November 22nd, 2021, deliberated and passed the Bill on granting reserved shares to incentive targets. The board of directors decided to set November 22, 2021 as the grant date for reserving some restricted shares, and agreed to encourage 21 people at the price of 13.68 yuan per share.
300246.SZ plans to invest 30 million yuan to set up Innovation Research Institute
Zhitong Financial APP News, 300246.SZ announcement, the company intends to set up a wholly-owned subsidiary Guangdong Baolite High-end Medical device Innovation Research Institute Co., Ltd. (tentative name, "Innovation Research Institute"). The registered capital of Innovation Research Institute is proposed to be 30 million yuan. After the completion of this investment, the company holds 100% equity interest in Innovation Research Institute.
300246.SZ granted 280000 restricted shares at a price of 13.68 yuan per share
Zhitong Financial APP, 300246.SZ announced that the company's "2021 restricted stock incentive plan (draft)" has achieved the conditions for the granting of restricted stock reservation, and the company's board of directors decided to take November 22nd, 2021 as the date for the grant of some restricted stock, and agreed to grant 280000 restricted shares to 21 incentive targets at a price of 13.68 yuan per share.
The 85th CMEF of Paulette | climbing does not only create the light of life.
Under the outline of the 2030-year Plan for healthy China, the demand for medical resources of the whole people will continue to rise in the future. With the development and popularization of intelligent technologies such as 5G, artificial intelligence and the Internet of things, clinical treatment in China will continue to develop into an intelligent era to provide a full range of life and health services for all. From October 13 to October 16, the four-day 85th China International Medical Devices (Autumn) Expo (CMEF) is being held in full swing at Shenzhen Baoan District International Convention and Exhibition Center. The Expo is based on innovative intelligent medical services with the theme of "innovative science and technology, smart collar future".
Paulette: the application for issuing shares to specific targets has been approved by the listing Review Center of the Shenzhen Stock Exchange.
Every time after AI newsletter, Paulette (SZ 300246, closing price: 18.44 yuan) issued an announcement on the evening of October 13 that the application for issuing shares to specific targets was approved by the listing examination Center of Shenzhen Stock Exchange. According to the announcement, on October 13, 2021, the company received a letter of opinion from the listing examination center of Shenzhen Stock Exchange on the application of Guangdong Baolaite Medical Technology Co., Ltd. to issue shares to specific targets. The Shenzhen Stock Exchange listing examination body examined the application documents submitted by the company to issue shares to specific objects and considered that the company complied with the issue articles.